Gain Therapeutics Inc
Company Profile
Business description
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Contact
4800 Montgomery Lane
Suite 220
BethesdaMD20814
USAT: +1 301 500-1556
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,039.80 | 82.70 | -0.91% |
| CAC 40 | 7,849.04 | 30.82 | 0.39% |
| DAX 40 | 23,635.39 | 276.21 | 1.18% |
| Dow JONES (US) | 46,098.30 | 79.98 | 0.17% |
| FTSE 100 | 9,221.20 | 25.54 | 0.28% |
| HKSE | 26,663.80 | 225.29 | 0.85% |
| NASDAQ | 22,506.47 | 245.14 | 1.10% |
| Nikkei 225 | 45,321.95 | 419.68 | 0.93% |
| NZX 50 Index | 13,120.03 | 114.86 | -0.87% |
| S&P 500 | 6,637.49 | 37.14 | 0.56% |
| S&P/ASX 200 | 8,754.80 | 93.70 | -1.06% |
| SSE Composite Index | 3,864.81 | 11.53 | -0.30% |